(S)-WAY 100135 dihydrochloride

Pricing Availability Delivery Time Qty
Cat.No. 1253 - (S)-WAY 100135 dihydrochloride | C24H33N3O2.2HCl | CAS No. 149007-54-5
Description: Potent, selective 5-HT1A antagonist
Chemical Name: (S)-N-tert-Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide dihydrochloride
Purity: ≥99% (HPLC)
Datasheet
Citations (3)
Reviews
Literature

Biological Activity

Potent, selective 5-HT1A receptor antagonist (IC50 = 15 nM). Selective over 5-HT1B, 1C, 2,α1, α2 and D2 receptors (IC50 > 1000 nM). Centrally active on systemic administration.

Licensing Information

Sold with the permission of Wyeth-Ayerst Research, US Patent 4,988,814

Technical Data

M. Wt 468.47
Formula C24H33N3O2.2HCl
Storage Desiccate at +4°C
Purity ≥99% (HPLC)
CAS Number 149007-54-5
PubChem ID 6604839
InChI Key NYZFUZCCDOSQBG-AWEZNQCLSA-N
Smiles O=C(NC(C)(C)C)[C@@]([C@]3=CC=CC=C3)([H])CN(CC2)CCN2C1=C(OC)C=CC=C1.Cl.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 46.85 100
water 2.34 5mM with gentle warming
water 4.68 10mM with sonication

Preparing Stock Solutions

The following data is based on the product molecular weight 468.47. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.13 mL 10.67 mL 21.35 mL
5 mM 0.43 mL 2.13 mL 4.27 mL
10 mM 0.21 mL 1.07 mL 2.13 mL
50 mM 0.04 mL 0.21 mL 0.43 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:
Safety Datasheet

References

References are publications that support the products' biological activity.

Cliffe et al (1993) (S)-N-tert-Butyl-3(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: a selective antagonist at presynaptic and postsynaptic 5-HT1A receptors. J.Med.Chem. 36 1509 PMID: 8496920

Fletcher et al (1993) WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors. Eur.J.Pharmacol. 237 283 PMID: 8365456

Fletcher et al (1993) Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents. Trends Pharmacol.Sci. 14 41 PMID: 8122313

Rodgers and Cole (1994) Anxiolytic-like effect of (S)-WAY 100135, a 5-HT1A receptor antagonist, in the murine elevated plus-maze test. Eur.J.Pharmacol. 261 321 PMID: 7813555


If you know of a relevant reference for (S)-WAY 100135 dihydrochloride, please let us know.

View Related Products by Target

View Related Products by Product Action

View all 5-HT1A Receptor Antagonists

Keywords: (S)-WAY 100135 dihydrochloride, supplier, Potent, selective, 5-HT1A, antagonist, Serotonin, Receptors, (S)-WAY100135, dihydrochloride, 5-HT1A, Receptors, 5-HT1A, Receptors, Tocris Bioscience

3 Citations for (S)-WAY 100135 dihydrochloride

Citations are publications that use Tocris products. Selected citations for (S)-WAY 100135 dihydrochloride include:

Borroto-Escuela et al (2012) The existence of FGFR1-5-HT1A receptor heterocomplexes in midbrain 5-HT neurons of the rat: relevance for neuroplasticity. J Neurosci 32 6295 PMID: 22553035

Grace et al (2012) 5-HT1A receptor-responsive pedunculopontine tegmental neurons suppress REM sleep and respiratory motor activity. J Neurosci 32 1622 PMID: 22302804

Foong et al (2010) 5-HT(1A), SST(1), and SST(2) receptors mediate inhibitory postsynaptic potentials in the submucous plexus of the guinea pig ileum. J Neurosci 298 G384 PMID: 20007849


Do you know of a great paper that uses (S)-WAY 100135 dihydrochloride from Tocris? If so please let us know.

Reviews for (S)-WAY 100135 dihydrochloride

There are currently no reviews for this product. Be the first to review (S)-WAY 100135 dihydrochloride and earn rewards!

Have you used (S)-WAY 100135 dihydrochloride?

Submit a review and receive an Amazon gift card.

$10US/$10CAN/€7/£6 gift card for a review without an image

$25US/$25CAN/€18/£15 gift card for a review with an image

*Offer only valid in the USA / Canada, UK and Europe

Submit a Review

Literature in this Area

GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
5-HT Receptors

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.